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Abstract 
Background: Serum immunoglobulin A antibodies against Epstein–Barr virus (EBV), viral capsid antigen (VCA‑IgA) 
and early antigen (EA‑IgA), are used to screen for nasopharyngeal carcinoma (NPC) in endemic areas. However, their 
routine use has been questioned because of a lack of specificity. This study aimed to determine the distributions of 
different subtypes of antibody and to illustrate how the natural variation patterns affect the specificity of screening in 
non‑NPC participants.
Methods: The distribution of baseline VCA‑IgA was analyzed between sexes and across 10‑year age groups in 18,286 
non‑NPC participants using Chi square tests. Fluctuations in the VCA‑IgA level were assessed in 1056 non‑NPC participants 
with at least two retests in the first 5‑year period (1987–1992) after the initial screening using the Kaplan–Meier method.
Results: The titers of VCA‑IgA increased with age (P < 0.001). Using a previous serological definition of high NPC risk, 
nasopharyngeal endoscopy and/or nasopharyngeal biopsy would be recommended in 55.5% of the non‑NPC partici‑
pants with an initial VCA‑IgA‑positive status and in 20.6% with an initial negative status during the 5‑year follow‑up. 
However, seroconversions were common; 85.2% of the participants with a VCA‑IgA‑positive status at baseline con‑
verted to negative, and all VCA‑IgA‑negative participants changed to positive at least once during the 5‑year follow‑
up. The EA‑IgA status had a high seroconversion probability (100%) from positive to negative; however, it had a low 
probability (19.6%) from negative to positive.
Conclusions: Age‑ and sex‑specific cutoff titer values for serum anti‑EBV antibodies as well as their specific titer fluc‑
tuation patterns should be considered when defining high NPC risk criteria for follow‑up diagnostics and monitoring.
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Background
Nasopharyngeal carcinoma (NPC) is rare in most 
regions of the world, with an incidence of less than 1 per 
100,000 person-years [1]. However, in some regions of 
South China and Southeast Asia, the incidence of NPC 
approaches 20–50 per 100,000 person-years [2, 3]. The 
pathogenesis is not fully understood; however, accu-
mulated evidence indicates that genetic susceptibility, 
Epstein–Barr virus (EBV) infection [4], and environmen-
tal factors, such as salted-fish consumption and ciga-
rette smoking, increase the risk of NPC development [5, 
6]. NPC easily spreads to the lymph nodes and distant 
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organs, and most patients are diagnosed only when the 
tumor has reached an advanced stage (stages III and IV) 
[7].
More than 95% of adults in some NPC endemic areas 
are infected with EBV. Infection typically occurs in child-
hood, and the virus remains in a latent phase within rest-
ing memory B cells under the strict monitoring of the 
immune system [8, 9]. However, the virus may be peri-
odically reactivated in response to environmental stress 
[5]. Several studies have reported that smoking [5], Can-
tonese-style salted fish [10], and Chinese herbs [11], all of 
which contain EBV-inducing substances, may drive EBV 
into the lytic cycle [12].
Given the unclear etiology of NPC, primary preven-
tion remains difficult, and the main strategy for reducing 
NPC mortality is to identify the disease at an early stage 
[13]. In the preclinical phase, serum antibodies against 
EBV-related antigens remain increased for an average of 
38  months [14–16], and the serological tests for these 
markers are simple and inexpensive [15]. Therefore, these 
antibodies have been used as screening markers for NPC 
in endemic areas since the 1970s. The immunoglobulin A 
(IgA) antibodies against viral capsid antigen (VCA-IgA) 
and early antigen (EA-IgA) are the most popular screen-
ing markers. VCA is the structural protein expressed by 
EBV during the late stage of the lytic cycle following viral 
DNA synthesis, whereas EA is a nonstructural protein 
expressed during the switch from the latent phase to lytic 
replication before viral DNA synthesis. The two markers 
have distinct features for NPC screening: VCA-IgA has 
a higher sensitivity than EA-IgA (79.6% vs. 31.6%); how-
ever, its specificity is lower than EA-IgA (92.0% vs. 99.7%) 
[13]. Thus, in practice, these two markers are typically 
used in combination for NPC screening [15, 17].
Several prospective screening studies have demon-
strated early detection rates for NPC of greater than 70% 
[15, 18, 19]. Nevertheless, EBV infection is ubiquitous; 
thus, routine use as a screening tool may have relatively 
low specificity, which may lead to potentially costly and 
invasive follow-up diagnostics [19–21]. Therefore, an 
investigation of the natural variations of EBV antibodies 
in non-NPC participants may identify particular serosta-
tus patterns for improved NPC screening.
In this study, we used EBV VCA-IgA and EA-IgA data 
from a prospective, population-based screening study 
with no clinical evidence of NPC during a median 15.9-
year follow-up in South China [17] to determine the dis-
tribution of baseline EBV VCA-IgA between sexes and 
among age groups as well as the long-term titer fluctua-
tions of the VCA-IgA and EA-IgA serostatus in non-NPC 
participants. The aim was to identify additional factors 




Serological EBV VCA-IgA and EA-IgA test results and fol-
low-up information were obtained from an NPC screen-
ing cohort from Sihui County, Guangdong Province, China 
[17]. Briefly, 18,411 eligible, non-NPC residents aged 
30–59 years in four towns of Sihui County were recruited 
in 1987 and 1992 (7774 in 1987 and 10,637 in 1992) [17]. 
Blood samples were collected at recruitment and tested 
for VCA-IgA using immunoenzymatic assay [22]. Partici-
pants positive at baseline for VCA-IgA were further tested 
for EA-IgA. High-risk individuals, including those with a 
VCA-IgA titer ≥1:40 or seropositive for both markers (cut-
off  =  1:5), were referred for nasopharyngeal endoscopic 
examination and/or pathological biopsy. We followed the 
participants every year from the initial screening until the 
diagnosis of NPC, migration, death, or the end of 2007, 
whichever event occurred first, using record links to the 
Cancer Register, Cause of Death Register, the Rosters of 
Village Committee, and the local Public Security Bureau in 
Sihui. The completeness of the Sihui Cancer Register has 
been described in detail previously [17]. A total of 125 par-
ticipants with NPC were identified at screening, leaving a 
total of 18,286 non-NPC participants in the present study. 
During a median 15.9 years of follow-up, 1276 non-NPC 
participants with a baseline VCA-IgA-positive status were 
advised to be repeatedly tested for VCA-IgA and EA-IgA 
every year. A total of 939 participants VCA-IgA-positive at 
baseline (73.6%) were retested at least twice during the first 
5-year follow-up. In addition, 160 of 17,010 participants 
VCA-IgA-negative at baseline were randomly selected to 
be retested for both screening markers every year, and 117 
of these participants (73.1%) were retested at least twice in 
the first 5 years. Finally, 1056 non-NPC participants with 
at least two VCA-IgA and EA-IgA retests in the initial 
5 years were included in the final analysis (Fig. 1).
Permission to use the data from the screening program 
and follow-up results was granted by the Institutional 
Ethics Review Board of Sun Yat-sen University Cancer 
Center (SYSUCC) (No. YP2009169).
Serological analysis
At baseline and each subsequent follow-up year, eligi-
ble participants were invited to donate 3  mL of blood 
to determine the VCA-IgA and EA-IgA statuses. Sero-
logical tests using immunoenzymatic assays were per-
formed in the laboratory of the SYSUCC as described 
previously [22]. A titer of 1:5 was defined as positive for 
VCA-IgA and EA-IgA. Titers were further classified into 
subgroups according to the maximum dilution of serum 
[17], with a VCA-IgA titer ≥1:40 or both VCA-IgA- and 
EA-IgA-positive (cutoff  =  1:5) defined as high risk for 
NPC.
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Quality control with a pooled serum sample as the 
standard has been used in every test conducted by the 
SYSUCC since the 1980s. The coefficient of variation 
(CV) of the assay for VCA-IgA over 8 years (1993–2000) 
was 8.37% [17].
Statistical analysis
The different serum levels of VCA-IgA were compared 
among 10-year age groups, between sexes, and accord-
ing to the recruitment time using Chi square tests. Linear 
trend tests for the association between age and VCA-IgA 
were performed with bidirectionally ordered variables.
The seroconversion of VCA-IgA was defined as a 
non-NPC participant with a VCA-IgA-negative status 
(cutoff =  1:5) at baseline changed to positive or with a 
VCA-IgA-positive status at baseline changed to nega-
tive at least once in the subsequent 5-year follow-up. The 
seroconversion of EA-IgA was defined the same as that of 
VCA-IgA. In the cumulative probability analysis, only the 
first change in status (from baseline negative to positive 
or from baseline positive to negative) was considered. The 
cumulative probability of seroconversion and the median 
duration of the original serum status were derived via the 
Kaplan–Meier method, with log-rank tests used to iden-
tify differences between sexes and the serum EBV status 
groups for the specific screening marker. Person-time 
was calculated from the baseline test to the first serum 
EBV change. The participants whose serum EBV status 
did not convert by the final visit at 5 years after screening 
were censored in the Kaplan–Meier analysis.
In the cumulative probability analysis of the partici-
pants who met the high-risk criteria, the outcome event 
was defined as a non-NPC participant with a baseline 
VCA-IgA ≥1:40 or both VCA-IgA and EA-IgA ≥1:5 at 
least once in the subsequent 5-year follow-up. The time 
to meet the high-risk criteria was calculated from the 
baseline test to the first visit at which a high risk criterion 
was identified. The cumulative probability was calculated 
using the Kaplan–Meier method.
All statistical analyses, unless otherwise noted, were 
performed using IBM Statistical Package for the Social 
Sciences Statistics 20 (IBM Corp, Chicago, IL, USA). All 
statistical tests were two-sided, and P < 0.05 was consid-
ered significant.
Eligible participants recruited in screening for NPC 
between 1987 and 1992 in Sihui (N = 18,411)
Retesting for VCA-IgA and EA-IgA at least 
2 times in the subsequent 5 years (n = 939)
Retesting for VCA-IgA and EA-IgA at least 2 
times in the subsequent 5 years (n = 117)
VCA-IgA-positive at baseline (n = 1276) VCA-IgA-negative at baseline (n = 17,010)
Randomly selected for testing EA-
IgA at baseline (n = 160)
Testing EA-IgA at baseline (n = 1268)
Excluded: Incident NPC cases (n = 125) in a 
median follow-up of 15.9 years 
Healthy participants after a median follow-
up of  15.9 years (n = 18,286)
Excluded: Participants without 
sufficient sera for EA-IgA (n = 8) 
Excluded: Retesting less than 2 times 
in the subsequent 5 years (n = 329) 
Excluded: Retesting less than 2 times 
in the subsequent 5 years (n = 43) 
Fig. 1 Recruitment diagram of the non‑nasopharyngeal carcinoma (NPC) population for the analysis of the long‑term variation trends of serum 
Epstein–Barr virus (EBV) antibodies. VCA-IgA immunoglobulin A (IgA) antibody against EBV viral capsid antigen; EA-IgA IgA antibody against EBV 
early antigen
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Results
Distribution of EBV antibodies in non‑NPC participants
A total of 18,286 non-NPC participants in the screening 
cohort were included for baseline EBV antibody analysis. 
The baseline EBV VCA-IgA seropositive rate was 7.0% 
(1276/18,286). As a result of insufficient sera for 8 partici-
pants, only 1268 participants were tested for EA-IgA, and 
3.2% (41/1268) of them were also positive for EA-IgA. 
The baseline seropositive rate of VCA-IgA was higher in 
males than in females (7.6% vs. 6.6%), and the difference 
was significant after adjusting for age (Mantel–Haen-
szel stratified χ2 = 7.286, P = 0.007). The VCA-IgA level 
increased significantly with age (Ptrends  <  0.05) in both 
males (χ2 = 11.844) and females (χ2 = 15.475) (Table 1). 
Using 1:40 as the cutoff value for a high NPC risk, the 
VCA-IgA positive rate in the 30–39 and 50–59 year age 
groups increased from 0.3% to 0.6% in males and from 
0.4% to 0.6% in females.
A total of 1056 participants were tested for VCA-IgA 
and EA-IgA at least twice after the initial screening, 
with 939 VCA-IgA-positive and 117 VCA-IgA-negative 
participants at baseline (Table  2). There was no differ-
ence in the sex ratio or age group distribution between 
the baseline VCA-IgA-positive and -negative partici-
pants. Using a VCA-IgA  ≥1:40 or both VCA-IgA- and 
EA-IgA-positive (cutoff = 1:5) as the threshold for naso-
pharyngeal endoscopy and/or pathological examination 
referral following NPC screening, the 5-year cumulative 
probability of seroconversion was 55.5% [95% confidence 
interval (CI) 49.4%–61.6%] for the participants with 
an initial VCA-IgA-positive status and 20.6% (95% CI 
12.4%–28.8%) for the participants with an initial VCA-
IgA-negative status. The 5-year cumulative probabilities 
for meeting either high-risk criterion were similar for 
males and females (Fig.  2). In the participants with an 
initial VCA-IgA-positive status, the cumulative prob-
ability of seroconversion was slightly higher in females 
than in males [56.0% (95% CI 49.7%–62.3%) vs. 50.4% 
(95% CI 41.6%–59.2%), P  =  0.052]. In the participants 
with an initial VCA-IgA-negative status, the cumulative 
probabilities did not differ between males and females 
(20.6% (95% CI 8.1%–33.1%) vs. 20.4% (95% CI 9.6%–
31.2%), P = 0.693].
Titer fluctuation patterns of EBV antibodies in the non‑NPC 
population
Long-term seroconversions were common for both VCA-
IgA and EA-IgA (Fig.  3). In the 939 initial VCA-IgA-
positive participants who received at least two retests, 
the median VCA-IgA-positive duration was 24  months 
(95% CI 23.3–24.7  months), and the cumulative prob-
ability of seroconversion within 5  years was 85.2% (95% 
CI 81.5%–88.9%) (Fig. 3a). In the 117 participants with an 
initial VCA-IgA-negative status retested at least twice, the 
median VCA-IgA-negative duration was 40 months (95% 
CI 35.1–44.9  months), and the 5-year cumulative prob-
ability of seroconversion was 100.0% (Fig. 3b).
In the non-NPC participants who met the high-risk 
criteria at baseline, the cumulative probability of sero-
conversion within 5  years was also high, with 33.8% 
(95% CI 25.4%–42.3%) for the participants with a VCA-
IgA ≥1:40, 42.0% (95% CI 31.2%–52.8%) for those with 
both VCA-IgA- and EA-IgA-positive, and 44.5% (95% CI 
36.1%–52.9%) for those fulfilling one of the two high-risk 
criteria that indicated conversion within 5 years.
In the 939 participants with an initial VCA-IgA-pos-
itive status and retested at least twice in the first 5-year 
Table 1 Baseline VCA-IgA distribution in 18,286 non-nasopharyngeal carcinoma (NPC) participants by age and sex
VCA-IgA immunoglobulin A (IgA) antibodies against viral capsid antigen of Epstein–Barr virus (EBV)
Sex Age (years) No. of  
participants
VCA‑IgA [cases (%)] χ2 P
– 1:5 1:10 1:20 ≥1:40
Male 30–39 3063 2861 (93.4) 108 (3.5) 69 (2.3) 16 (0.5) 9 (0.3)
40–49 2196 2022 (92.1) 68 (3.1) 76 (3.5) 23 (1.0) 7 (0.3) 11.844 0.001
50–59 1740 1584 (91.0) 73 (4.2) 57 (3.3) 16 (0.9) 10 (0.6)
Female 30–39 5541 5225 (94.3) 139 (2.5) 129 (2.3) 27 (0.5) 21 (0.4)
40–49 3070 2855 (93.0) 93 (3.0) 83 (2.7) 24 (0.8) 15 (0.5) 15.475 0.000
50–59 2676 2463 (92.0) 96 (3.6) 71 (2.7) 30 (1.1) 16 (0.6)
Table 2 Baseline VCA-IgA-positive and  -negative statuses 
in 1056 non-NPC participants by age and sex
Subgroup VCA‑IgA‑negative VCA‑IgA‑positive χ2 P
Gender
 Male 50 388 0.086 0.770
 Female 67 551
Age (years)
 30–39 44 392 1.230 0.541
 40–49 43 299
 50–59 30 248
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follow-up, 32 were also positive for EA-IgA. However, 
none of the 117 participants with an initial VCA-Ig-neg-
ative status were positive for EA-IgA. Compared with 
VCA-IgA, EA-IgA had a higher seroconversion prob-
ability from positive to negative (P = 0.001) and a lower 
probability from negative to positive (P < 0.001) (Fig. 3). 
The median duration of an EA-IgA-positive status was 
14  months (95% CI 11.3–16.6  months), and all 32 par-
ticipants converted to negative in the 5-year follow-up. 
Of the 1024 participants with an initial EA-IgA-negative 
status, the 5-year cumulative probability of seroconver-
sion was 19.6% (95% CI 14.3%–24.9%). Furthermore, the 
cumulative probability of seroconversion for serum EBV 
antibodies did not differ significantly between males and 
females (Fig.  3c–f). In the participants with an initial 
VCA-IgA-positive status, the cumulative probability of 
seroconversion was 88.1% in males (95% CI 83.2%–93.0%) 
and 83.0% in females (95% CI 77.7%–88.3%). In the partic-
ipants with an initial VCA-IgA-negative status, the cumu-
lative probability was 100.0% in males and 82.7% (95% CI 
71.9%–93.5%) in females. In the participants with an ini-
tial EA-IgA-positive status, the cumulative probabilities 
were 100.0% for both males and females. In the partici-
pants with an initial EA-IgA-negative status, the cumula-
tive probability was 17.7% (95% CI 11.8%–23.6%) in males 
and 21.0% (95% CI 13.2%–28.8%) in females.
Discussion
The current findings indicated that the baseline EBV 
VCA-IgA-positive rate was 7.6% in males and 6.6% in 
females, and the positive rate tended to increase with 
age from 6.0% in the 30–39  year age group to 8.4% in 
the 50–59 year age group. These findings are consistent 
with the epidemiological characteristics of areas with 
a high NPC risk, with increased incidence in males and 
peak incidence among the population aged 50–59 years 
[3]. Therefore, an age- and sex-dependent high-risk cut-
off value for VCA-IgA should be considered. The cur-
rently recommended referral criteria for nasopharyngeal 
endoscopy and biopsy (VCA-IgA  ≥1:40 and/or VCA-
IgA and EA-IgA double positive) may be appropriate for 
men of 30–39 years old; however, these criteria become 
less specific with age and may thus increase the possi-
bility of unnecessary diagnostic tests in participants of 
50–59 years old. Larger randomized clinical trials should 
be conducted to further address this concern.
Titer fluctuations in the EBV antibody serostatus were 
common in this non-NPC population. In a previous NPC 
screening study in an endemic area, many non-NPC par-
ticipants were advised to undergo expensive and invasive 
nasopharyngeal endoscopy and biopsy examinations as a 
result of increased serum EBV antibodies [14]. Our find-























Time after recruitment (months)
Male      50         50          43          42          41          41
Female   67        67          57          57           55
Male      367      367        261        248        240
Female  507      507        331        315        303      302
Initial VCA-IgA  positive Initial VCA-IgA  negative a b
Log-rank test, χ2 = 0.156, P = 0.693
Number at risk 
Log-rank test, χ2 = 3.465, P = 0.052
Number at risk 
Fig. 2 Cumulative probability for the male and female participants with an initial VCA‑IgA‑positive or ‑negative status who met the high risk criteria 
in the first 5‑year follow‑up. a Cumulative probabilities of seroconversion for meeting any of the high risk criteria in the participants with an initial 
VCA‑IgA‑positive status were not different between males and females; b cumulative probabilities of seroconversion for meeting any of the high 
risk criteria in the participants with an initial VCA‑IgA‑negative status were similar for males and females
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initial VCA-IgA-positive status met the high-risk criteria, 
whereas 20.6% of the participants with an initial VCA-
IgA-negative status met the high-risk criteria at least 
once during the first 5-year study period. One potential 
strategy for reducing unnecessary follow-up examina-
tions is to repeatedly test for serum EBV antibodies 
several weeks before referral for endoscopy and naso-
pharyngeal biopsy to not only preclude random measure-
ment errors but also eliminate participants who exhibit 
a short-term EBV antibody increase caused by environ-
mental factors. If the repeated tests indicate that the anti-
body levels remain increased, a fiberscopic examination 
or biopsy is recommended. Otherwise, these expensive 
and invasive examinations may be avoided.
Approximately 85.2% of the participants with an initial 
VCA-IgA-positive status converted to negative within 
5  years. However, we determined that the seroconver-
sion rate of NPC participants from positive to negative 
was substantially lower (15.4%) in our original study 
(P  <  0.001) [17] than the seroconversion rate of non-
NPC participants. This finding suggested that serum EBV 
antibody titer fluctuation may be used to determine the 
optimal screening interval. Similar to several other NPC 
screening studies in South China [14, 15], the preset 
screening interval was 1 year for participants with both 
VCA-IgA and EA-IgA positive, and the positive predic-
tive value was less than 1% [13, 15]. We speculated that 
the use of results from only one test to determine the 
clinical screening interval does not take into account 
transient increases induced by environmental stressors, 
which may thus result in many false-positive evaluations. 
Thus, a rational screening interval for participants with 
EBV seropositive at baseline may be adjusted by retest 
results. If the repeated EBV antibody tests remain posi-
tive, then a retest in 1 year should be recommended. In 
contrast, the screening interval may be prolonged in neg-
ative cases.
These frequent seroconversions of EBV antibod-
ies may arise from environmental inducers that change 
throughout an individual’s lifetime. The virus is typically 
restricted to resting memory B cells by the host immune 
system; however, it may be periodically reactivated. Fol-
lowing EBV reactivation, it switches from a latent phase 
to a lytic phase with concomitant expression of viral 
antigens. The host immune system produces a series of 
antibodies against viral antigens, especially IgA antibod-
ies against lytic phase antigens, including VCA-IgA and 
EA-IgA. The living environment may frequently change. 
When these inducers are eliminated, the virus may return 
to the latent state in memory B cells, and the serum anti-
body levels gradually decrease, which results in serocon-
version to a negative status.
We determined that the seroconversion rate of EA-IgA 
from positive to negative was significantly higher than 
that of VCA-IgA in the first 5-year period (100.0% vs. 
85.2%, P  =  0.001). In contrast, the seroconversion rate 
of EA-IgA from negative to positive was lower than that 
of VCA-IgA (19.6% vs. 100.0%, P < 0.001). A high-spec-
ificity screening marker must yield a low false-positive 
rate throughout the screening course for the non-disease 
population. Our previous study [13] and other studies 
[16, 21] have reported that the baseline EA-IgA-positive 
status is lower than the VCA-IgA-positive status in the 
non-NPC population. Furthermore, VCA-IgA exhibited 
a higher two-way seroconversion rate (from negative to 
positive and from positive to negative) in the non-NPC 
population, whereas the EA-IgA conversion was only 
one-way (from positive to negative). This pattern results 
in a higher false-positive rate for VCA-IgA and a higher 
specificity for EA-IgA during follow-up. Thus, EA-IgA 
may be more specific for NPC screening than VCA-IgA.
This study had several limitations. First, the study was 
conducted in Sihui County, China, which has a high 
NPC incidence worldwide. Therefore, the results may 
not be translated to other populations in medium- or 
low-incidence areas. However, NPC screening is more 
likely to succeed if conducted in a high-risk population; 
thus, these findings are useful for developing screen-
ing strategies for this population. Second, the partici-
pants recruited for NPC screening may not represent 
the general population. For example, screening partici-
pants may be healthier or more health-conscious than 
the general population. However, no report to date has 
demonstrated that the serum EBV antibody status in the 
non-NPC population is affected by compliance for NPC 
screening.
In summary, serum EBV antibody levels in a non-NPC 
population from an endemic area were increased in 
(See figure on previous page.) 
Fig. 3 Kaplan–Meier estimates of the cumulative probability of seroconversion for the non‑NPC participants with different baseline serum statuses 
of VCA‑IgA and EA‑IgA in the first 5‑year follow‑up. a Cumulative probability of seroconversion from positive to negative for VCA‑IgA differed from 
that for EA‑IgA. b Cumulative probability of seroconversion from negative to positive for VCA‑IgA was higher than that for EA‑IgA. c Cumulative 
probabilities of seroconversion from positive to negative for VCA‑IgA were similar between males and females. d Cumulative probability of sero‑
conversion from negative to positive for VCA‑IgA in males resembled the probability in females. e Cumulative probabilities of seroconversion from 
positive to negative for EA‑IgA did not differ between males and females. f Cumulative probabilities of seroconversion from negative to positive for 
EA‑IgA did not differ between males and females
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males and older participants. Thus, an age- and sex-spe-
cific cutoff for the anti-EBV antibody level should be con-
sidered for NPC screening. Repeated testing indicated 
that EBV seroconversions were common in the non-NPC 
population. This finding may contribute to the design of 
more efficient NPC screening strategies with a rational 
adjustment of rest-retest intervals.
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